Prognostic and clinical significance of expressions of P53, Erbb2, c-Kit and Bcl2 in childhood medulloblastoma
Abstract
Purpose: The objective of this study is to evaluate prognostic implications of clinical, histopathological features and immuhistochemical expressions of p53, ERBB2, c-Kit and Bcl-2 in pediatric medulloblastoma. Materials and Methods: A total of 29 pediatric medulloblastoma cases were evaluated for prognostic association of demographic, clinical, histopathological features and immunohistochemical expressions of p53, ERBB2, c-Kit and Bcl-2. Results: Median age at diagnosis was 69 months (21-122 months). Median duration of follow-up was 54 months (2-209 months). Fourteen of samples were diagnosed as classical (48%), thirteen cases as nodular/desmoplastic (45%) and two cases as anaplastic (7%) subtype. Staining for c-Kit, Bcl-2, p53 and ERBB2 was positive in 28, 10, 9 and 2 samples, respectively. Overall (OS) and event-free survival (EFS) were 62 % and 52%, respectively. Bcl-2 expression was found to be significantly increased in nodular/desmoplastic subtype. None of the clinical, histopathological and immunohistochemical features were related to survival. Conclusion: This study reflects the earliest periods of current multimodal treatment protocols of medulloblastoma with similar survival rates in literature. Although none of the proposed factors have been associated with survival, future studies combining molecular and immunohistochemical methods would be more convenient for detecting new prognostic criteria in pediatric medulloblastoma.
Keywords
Kaynakça
- 1. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma inchildren: Conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-845.
- 2. Chintagumpala M, Berg S, Blaney SM. Treatment contraversies in medulloblastoma. Curr Opin Oncol, 2001; 13: 154–159
- 3. Edward C Schwalbe, Janet C Lindsey, Sirintra Nakjang, Stephen Crosier, Amanda J Smith, Debbie Hicks et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017; 18(7): 958–971.
- 4. Gajjar AJ, Robinson GW. Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol. 2014;11(12):714-22
- 5. Michael D. Taylor, Paul A. Northcott, Andrey Korshunov, Marc Remke, Yoon-Jae Cho, Steven C. Clifford et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465-72.
- 6. Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015; 20;33(24):2646-54.
- 7. Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR et al. Rethinking medulloblastoma from a targeted therapeutics perspective. J Neurooncol. 2018 ; 5
- 8. Gessi M, von Bueren AO, Rutkowski S, Pietsch T. p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. J Neurooncol. 2012;106(1):135-41
- 9. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002 ;61(3):215-25; discussion 226-9.
- 10. Ramaswamy, V., M. Remke, J. Adamski, U. Bartels, U. Tabori, X. Wang, et al. 2016. Medulloblastoma subgroup-specificoutcomes in irradiated children: who are the true high-risk patients? Neuro. Oncol.18:291–297.
